Overview

  • Product nameAnti-Collagen I antibody
    See all Collagen I primary antibodies
  • Description
    Rabbit polyclonal to Collagen I
  • SpecificityTypically less than 1% cross reactivity against other types of collagens was detected by ELISA against purified standards. Some class specific anti-collagens may be specific for three-dimensional epitopes which may result in diminished reactivity with denatured collagen or formalin-fixed, paraffin embedded tissues. This antibody reacts with most mammalian Type I collagens and has negligible cross-reactivity with Type II, III, IV, V or VI collagens. Non-specific cross-reaction of anti-collagen antibodies with other human serum proteins or non-collagen extracellular matrix proteins is negligible.
  • Tested applicationsIHC-Fr, Indirect ELISA, WB, ELISA, ICC/IF, IPmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Goat, Horse, Cow, Human, Pig
  • Immunogen

    Full length native protein (purified) corresponding to Human Collagen I aa 1-1464.
    Database link: P02452

  • Positive control
    • Wistar Rat hepatic stellate cell lysate [GFP transduced], for Western blotting.
  • General notes

    It is often extremely difficult to generate antibodies with specificities to collagens due to the uninterrupted "Glycine-X-Y" triplet repeat that is a necessary part of the triple helical structure. The development of type specific antibodies is dependent on NON-DENATURED three-dimensional epitopes - this may result in diminished reactivity of some antibodies with denatured collagen or formalin-fixed, paraffin embedded tissues. Anti-Collagen antibodies have been used for indirect trapping ELISA for quantitation of antigen in serum using a standard curve, for immunoprecipitation and for native (non-denaturing, non-dissociating) PAGE and western blotting for highly sensitive qualitative analysis.

Properties

  • FormLiquid
  • Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
  • Storage bufferPreservative: 0.01% Sodium Azide
    Constituents: 0.125M Sodium borate, 0.075M Sodium chloride, 0.005M EDTA. pH 8.0
  • Concentration information loading...
  • PurityImmunogen affinity purified
  • Purification notesThis antibody has been prepared by immunoaffinity chromatography using immobilized antigens followed by extensive cross-adsorption against other collagens, human serum proteins and non-collagen extracellular matrix proteins to remove any unwanted specificities. Sterile filtered.
  • Clonality Polyclonal
  • IsotypeIgG
  • Research Areas

Applications

Our Abpromise guarantee covers the use of ab34710 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-Fr 1/50 - 1/200.
Indirect ELISA 1/5000 - 1/50000.
WB 1/5000 - 1/10000. This product is not recommended for use under denaturing conditions in WB, IP, and ELISA. We would suggest testing it under native conditions. Denaturing and reducing conditions will greatly diminish reactivity and selectivity of this antibody.
ELISA 1/5000 - 1/50000.
ICC/IF 1/500.
IP 1/100.

Target

  • FunctionType I collagen is a member of group I collagen (fibrillar forming collagen).
  • Tissue specificityForms the fibrils of tendon, ligaments and bones. In bones the fibrils are mineralized with calcium hydroxyapatite.
  • Involvement in diseaseDefects in COL1A1 are the cause of Caffey disease (CAFFD) [MIM:114000]; also known as infantile cortical hyperostosis. Caffey disease is characterized by an infantile episode of massive subperiosteal new bone formation that typically involves the diaphyses of the long bones, mandible, and clavicles. The involved bones may also appear inflamed, with painful swelling and systemic fever often accompanying the illness. The bone changes usually begin before 5 months of age and resolve before 2 years of age.
    Defects in COL1A1 are a cause of Ehlers-Danlos syndrome type 1 (EDS1) [MIM:130000]; also known as Ehlers-Danlos syndrome gravis. EDS is a connective tissue disorder characterized by hyperextensible skin, atrophic cutaneous scars due to tissue fragility and joint hyperlaxity. EDS1 is the severe form of classic Ehlers-Danlos syndrome.
    Defects in COL1A1 are the cause of Ehlers-Danlos syndrome type 7A (EDS7A) [MIM:130060]; also known as autosomal dominant Ehlers-Danlos syndrome type VII. EDS is a connective tissue disorder characterized by hyperextensible skin, atrophic cutaneous scars due to tissue fragility and joint hyperlaxity. EDS7A is marked by bilateral congenital hip dislocation, hyperlaxity of the joints, and recurrent partial dislocations.
    Defects in COL1A1 are a cause of osteogenesis imperfecta type 1 (OI1) [MIM:166200]. A dominantly inherited connective tissue disorder characterized by bone fragility and blue sclerae. Osteogenesis imperfecta type 1 is non-deforming with normal height or mild short stature, and no dentinogenesis imperfecta.
    Defects in COL1A1 are a cause of osteogenesis imperfecta type 2A (OI2A) [MIM:166210]; also known as osteogenesis imperfecta congenita. A connective tissue disorder characterized by bone fragility, with many perinatal fractures, severe bowing of long bones, undermineralization, and death in the perinatal period due to respiratory insufficiency.
    Defects in COL1A1 are a cause of osteogenesis imperfecta type 3 (OI3) [MIM:259420]. A connective tissue disorder characterized by progressively deforming bones, very short stature, a triangular face, severe scoliosis, grayish sclera, and dentinogenesis imperfecta.
    Defects in COL1A1 are a cause of osteogenesis imperfecta type 4 (OI4) [MIM:166220]; also known as osteogenesis imperfecta with normal sclerae. A connective tissue disorder characterized by moderately short stature, mild to moderate scoliosis, grayish or white sclera and dentinogenesis imperfecta.
    Genetic variations in COL1A1 are a cause of susceptibility to osteoporosis (OSTEOP) [MIM:166710]; also known as involutional or senile osteoporosis or postmenopausal osteoporosis. Osteoporosis is characterized by reduced bone mass, disruption of bone microarchitecture without alteration in the composition of bone. Osteoporotic bones are more at risk of fracture.
    Note=A chromosomal aberration involving COL1A1 is found in dermatofibrosarcoma protuberans. Translocation t(17;22)(q22;q13) with PDGF.
  • Sequence similaritiesBelongs to the fibrillar collagen family.
    Contains 1 fibrillar collagen NC1 domain.
    Contains 1 VWFC domain.
  • Post-translational
    modifications
    Proline residues at the third position of the tripeptide repeating unit (G-X-Y) are hydroxylated in some or all of the chains. Proline residues at the second position of the tripeptide repeating unit (G-X-Y) are hydroxylated in some of the chains.
    O-linked glycan consists of a Glc-Gal disaccharide bound to the oxygen atom of a post-translationally added hydroxyl group.
  • Cellular localizationSecreted > extracellular space > extracellular matrix.
  • Information by UniProt
  • Database links
  • Alternative names
    • Alpha 1 type I collagen antibody
    • Alpha 2 type I collagen antibody
    • Alpha-1 type I collagen antibody
    • CO1A1_HUMAN antibody
    • COL1A1 antibody
    • COL1A2 antibody
    • Collagen alpha-1(I) chain antibody
    • Collagen I alpha 1 polypeptide antibody
    • Collagen I alpha 2 polypeptide antibody
    • Collagen Of Skin Tendon And Bone antibody
    • Collagen Type 1 antibody
    • Collagen type I alpha 1 antibody
    • Collagen type I alpha 2 antibody
    • OI4 antibody
    • Osteogenesis Imperfecta Type IV antibody
    • Pro alpha 1(I) collagen antibody
    • Type I procollagen antibody
    see all

Anti-Collagen I antibody images

  • ab34710 staining mouse kidney sections (ab4606) by IHC-Fr. Kidney tissue was cryoprotected with 30% sucrose, sectioned using a cryostat at 10 microns and mounted onto slides. After drying overnight in fume hood, sections were fixed in 4% formalin in PBS for 10 minutes. Blocking was performed with 1% BSA for 10 minutes at 21°C. Staining with ab34710 at a 1/100 dilution in TBS/BSA with 0.02% azide was performed for 2h at 21°C. A conjugated goat anti-rabbit 594 polyclonal antibody at 1/1000 was used as the secondary antibody.

    See Abreview

  • ab34710 staining Collagen I in horse bronchial fibroblast cells by Immunocytochemistry. Cells were fixed with acetone and blocking with 3% BSA was performed for 1 hour 30 minutes at 40°C. Samples were incubated with primary antibody (1/500: in 3% BSA/ PBS) for 12 hours at 4°C. An FITC-conjugated goat polyclonal to rabbit IgG was used at dilution at 1/160 as secondary antibody.

    See Abreview

  • Anti-Collagen I antibody (ab34710) at 1/1000 dilution + Human Collagen

    Secondary
    DyLight™ 649 anti-rabbit secondary antibody at 1:20,000 for 30 min at RT at 1/20000 dilution

    Lane 1: Human Collagen Type 1. 50 ng per lane.

    Other Band(s): Collagen Type I splice variants and isoforms.


  • developed using the ECL technique

    Performed under non-reducing conditions.
    Detection of collagen I in Wistar rat hepatic stellate cells in GFP-transduced (left lane) and PPAR?-transduced cell lysates (right lane). Protein staining shown below each blot depicts equal protein loading. An equal amount of the whole cell protein (100 µg) was separated by native PAGE and electroblotted to nitrocellulose membranes. Proteins were detected by incubating the membrane with anti-Collagen I antibody at a concentration of 0.2–2 µg/10 ml in TBS with 5% Non-fat milk.

References for Anti-Collagen I antibody (ab34710)

This product has been referenced in:
  • Majumder B  et al. Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. Nat Commun 6:6169 (2015). IHC-P ; Human . Read more (PubMed: 25721094) »
  • Xu L  et al. Total polysaccharide of Yupingfeng protects against bleomycin-induced pulmonary fibrosis via inhibiting transforming growth factor-ß1-mediated type I collagen abnormal deposition in rats. J Pharm Pharmacol N/A:N/A (2014). Rat . Read more (PubMed: 25209833) »

See all 70 Publications for this product

Product Wall

Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Sample Human Tissue sections (pancreatic tumor)
Antigen retrieval step Heat mediated - Buffer/Enzyme Used: 10mM Citrate buffer pH 6
Permeabilization No
Specification pancreatic tumor
Blocking step Serum as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 21°C
Fixative 10% buffered formalin
Username

Abcam user community

Verified customer

Submitted Aug 11 2015

Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Sample Mouse Tissue sections (Breast tumor xenograft)
Antigen retrieval step Heat mediated - Buffer/Enzyme Used: 10mM Citrate buffer pH 6
Permeabilization No
Specification Breast tumor xenograft
Blocking step Serum as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 21°C
Fixative 10% buffered formalin
Username

Abcam user community

Verified customer

Submitted Aug 11 2015

Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Sample Chicken Tissue sections (Oesophagus)
Antigen retrieval step Heat mediated - Buffer/Enzyme Used: Citric acid
Permeabilization No
Specification Oesophagus
Blocking step BSA as blocking agent for 10 minute(s) · Concentration: 2% · Temperature: 21°C
Fixative Formaldehyde
Username

Mr. Carl Hobbs

Verified customer

Submitted Jul 30 2015

Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Sample Human Tissue sections (HNSCC Tissue)
Antigen retrieval step Heat mediated
Permeabilization No
Specification HNSCC Tissue
Blocking step Serum as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 10% · Temperature: 25°C
Fixative Formaldehyde
Username

Dr. Biswanath Majumder

Verified customer

Submitted Jul 01 2015

Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Blocking step BSA as blocking agent for 20 minute(s) · Concentration: 1% · Temperature: 25°C
Antigen retrieval step Heat mediated - Buffer/Enzyme Used: Citrate Buffer, pH6.0
Sample Rat Tissue sections (Brain)
Specification Brain
Permeabilization No
Fixative Formaldehyde
Username

Abcam user community

Verified customer

Submitted Mar 10 2015

Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Blocking step Serum as blocking agent for 30 minute(s) · Concentration: 2.5% · Temperature: 25°C
Antigen retrieval step Heat mediated - Buffer/Enzyme Used: 10 mM sodium citrate
Sample Mouse Tissue sections (lung)
Specification lung
Permeabilization No
Fixative Formalin
Username

Abcam user community

Verified customer

Submitted Jan 02 2015

Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Blocking step BSA as blocking agent for 10 minute(s) · Concentration: 1% · Temperature: 21°C
Antigen retrieval step Heat mediated - Buffer/Enzyme Used: Citric acid
Sample Pig Tissue sections (Small intestine)
Specification Small intestine
Permeabilization No
Fixative Formaldehyde
Username

Mr. Carl Hobbs

Verified customer

Submitted Nov 03 2014

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Immunohistochemistry (Frozen sections)
Blocking step Serum as blocking agent for 15 minute(s) · Concentration: 10% · Temperature: 25°C
Sample Human Tissue sections (cell pellet)
Specification cell pellet
Permeabilization No
Fixative Paraformaldehyde
Username

Abcam user community

Verified customer

Submitted Jun 28 2013

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Immunocytochemistry/ Immunofluorescence
Sample Mouse Cell (Osteoblast)
Specification Osteoblast
Fixative Formaldehyde
Permeabilization No
Blocking step BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 3% · Temperature: 25°C
Username

Abcam user community

Verified customer

Submitted May 16 2013

I think the antibodies should be fine if they were only at +10C for that short a period of time. Most of our antibodies will remain stable at room temperature for up to 7 days without any negative effect.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"